Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lupus clue: can a heart drug reveal hidden disease markers?

NCT ID NCT02320357

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small pilot study looked at whether clopidogrel, a drug that stops blood clots, could lower a substance called sCD40L in people with lupus. Lupus is an autoimmune disease where the body attacks itself. The study involved 18 adults with lupus and measured sCD40L levels in their blood. The goal was to learn more about the disease, not to treat it directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

18 people

The number who actually took part.

Started

Aug 2015

Finished

Sep 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of SLE according to revised criteria of American College of Rheumatology * Being affiliated to health insurance * Having signed an informed consent (later than the day of inclusion and before any examination required by research) Exclusion Criteria: * \> 20mg/day of prednisone equivalent for \> 7 days 30 days before the pre-inclusion. * Diseases flare 3 months before the inclusion. A disease flare is defined by an increase of SLEDAI score \>3 and or a change of the immunosuppressive treatment and or an increase of steroids dose. * Is treated or has received 3 months before the pre-inclusion steroids pulses or intravenous immunoglobulins. * Renal involvement that could required a kidney biopsy. * Required surgery in the next 12 weeks. * Has been treated by cyclophosphamide 3 months before the pre-inclusion. * Has been treated by biotherapy 6 months before the pre-inclusion. * Contraindication to clopidogrel (annex 1). * History of cancer except healed basal cell carcinoma. * History of severe hemorrhage * Disease exposing to hemorrhage * Associated antiphospholipid syndrome * Pregnant or breastfeeding women * No contraception for women of childbearing age * Severe hypertension * Ongoing statin, non-steroidal anti-inflammatory, antiplatelet and anticoagulant drugs. * Being under guardianship * Patient participating at an other biomedical research with an exclusion period at the screening visit.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic lupus erythematous are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyper-IgM syndrome systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic lupus erythematous

Contacts and locations

Locations

  • Service de Médecine Interne

    Limoges, 87000, France

  • Service de Médecine Interne et Immunopathologie

    Toulouse, 31 000, France

  • Service de Médecine Interne et maladies Infectieuses - Hôpital Saint-André

    Bordeaux, Bordeaux, 33075, France